首页> 美国卫生研究院文献>Scientific Reports >Development of a novel UHPLC-MS/MS-based platform to quantify amines amino acids and methylarginines for applications in human disease phenotyping
【2h】

Development of a novel UHPLC-MS/MS-based platform to quantify amines amino acids and methylarginines for applications in human disease phenotyping

机译:开发基于UHPLC-MS / MS的新型平台以定量用于人类疾病表型的胺氨基酸和甲基精氨酸

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Amine quantification is an important strategy in patient stratification and personalised medicine. This is because amines, including amino acids and methylarginines impact on many homeostatic processes. One important pathway regulated by amine levels is nitric oxide synthase (NOS). NOS is regulated by levels of (i) the substrate, arginine, (ii) amino acids which cycle with arginine and (iii) methylarginine inhibitors of NOS. However, biomarker research in this area is hindered by the lack of a unified analytical platform. Thus, the development of a common metabolomics platform, where a wide range of amino acids and methylarginines can be measured constitutes an important unmet need. Here we report a novel high-throughput ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) platform where ≈40 amine analytes, including arginine and methylarginines can be detected and quantified on a molar basis, in a single sample of human plasma. To validate the platform and to generate biomarkers, human plasma from a well-defined cohort of patients before and after coronary artery bypass surgery, who developed systemic inflammatory response syndrome (SIRS), were analysed. Bypass surgery with SIRS significantly altered 26 amine analytes, including arginine and ADMA. Consequently, pathway analysis revealed significant changes in a range of pathways including those associated with NOS.
机译:胺定量是患者分层和个性化治疗的重要策略。这是因为胺(包括氨基酸和甲基精氨酸)会影响许多体内平衡过程。一氧化氮合酶(NOS)是受胺水平调节的重要途径。 NOS受以下因素调节:(i)底物,精氨酸,(ii)与精氨酸循环的氨基酸和(iii)NOS的甲基精氨酸抑制剂。然而,由于缺乏统一的分析平台,阻碍了该领域中生物标志物的研究。因此,开发一种通用的代谢组学平台(可以测量广泛的氨基酸和甲基精氨酸)构成了一个重要的未满足需求。在这里,我们报告了一种新颖的高通量超高效液相色谱-串联质谱(UHPLC-MS / MS)平台,该平台可在单个样品中检测并定量测定约40种胺分析物(包括精氨酸和甲基精氨酸)人血浆。为了验证平台并生成生物标志物,分析了明确定义的冠状动脉搭桥手术前后患者的血浆,这些患者发生了全身性炎症反应综合征(SIRS)。 SIRS绕过手术显着改变了26种胺分析物,包括精氨酸和ADMA。因此,途径分析揭示了包括NOS相关途径在内的一系列途径的显着变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号